| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 146,10 | 146,40 | 28.01. | |
| 145,90 | 146,75 | 28.01. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 285,00 | 10 | |||
| 266,00 | 40 | |||
| 244,00 | 35 | |||
| 222,00 | 50 | |||
| 175,00 | 24 | |||
| 144,70 | 84 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 42 | 144,20 | |||
| 42 | 144,15 | |||
| 40 | 1,234 | |||
| 1.063 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.187 | 0,205 | 243 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:24:08 | 144,20 | 9 |
| 16:44:06 | 143,80 | 11 |
| 16:31:54 | 143,05 | 6 |
| 15:13:57 | 145,30 | 10 |
| 14:32:41 | 143,75 | 6 |
| 13:38:07 | 146,10 | 10 |
| 13:30:52 | 143,70 | 22 |
| 13:30:00 | 145,75 | 70 |
| 13:30:00 | 145,40 | 28 |
| 13:30:00 | 145,35 | 30 |
| 09:16:36 | 145,55 | 10 |
| Tagesumsatz Xetra | -0,70 -0,48 % | 1.821 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | 248 | AFX News | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| Mi | FDA erteilt Biogen-Medikament Litifilimab Status als bahnbrechende Therapie | 6 | Investing.com Deutsch | ||
| Mi | FDA grants breakthrough therapy designation to Biogen's litifilimab | 6 | Investing.com | ||
| Mi | Biogen Inc.: Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options | 209 | GlobeNewswire (Europe) | Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab... ► Artikel lesen | |
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Di | Expert Outlook: Biogen Through The Eyes Of 11 Analysts | 3 | Benzinga.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain | ACCESS Newswire | ~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")... ► Artikel lesen | |
| 00:24 | GenSight Biologics S.A.: GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
| Mi | BioNTech ernennt Kylie Jimenez zur Chief People Officer | 4investors | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| Mi | NurExone ebnet den Weg für klinischen Start von ExoPTEN | Small- & Micro Cap Investment | ||
| Mi | Morning Market Movers: Murano Global Investments, Flora Growth, Kustom Entertainment, Ainos See Big Swings | AFX News | OTTAWA (dpa-AFX) - At 7:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |